GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Summary: Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morb...

Full description

Bibliographic Details
Main Authors: Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Cell Reports Medicine
Subjects:
Glucagon-like peptide-1 receptor agonists
GLP-1 RA
liraglutide
MC4R mutation
obesity
weight loss
Online Access:http://www.sciencedirect.com/science/article/pii/S2666379120300069

Internet

http://www.sciencedirect.com/science/article/pii/S2666379120300069

Similar Items